Does Dabrafenib Plus Trametinib Offer Survival Benefit in Metastatic Melanoma?

Source: Cancer Network, October 2019

Dabrafenib plus trametinib as a first-line treatment demonstrated long-term survival benefit for approximately one-third of patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, a 5-year pooled analysis of two phase III trials revealed. The findings were recently published in the New England Journal of Medicine.

“Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors,” the study authors explained. “However, long-term clinical outcomes in these patients remain undefined.”

The pooled analysis included extended-survival data from the COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy. Specifically, the COMBI-d trial used dabrafenib plus placebo as the comparator arm and the COMBI-v trial used vemurafenib alone as the comparator arm.

Read the original full article